Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27920846 | 0.98 | LMNA (0.52) | LMNACA1TSHRMAPTHTT | |
| Ammonia Solution, Strong SCHEMBL28576941 | 0.98 | LMNA (0.52) | LMNACA1TSHRMAPTHTT | |
| Hydrochloric Acid SCHEMBL30807186 | 0.98 | LMNA (0.52) | LMNACA1TSHRMAPTHTT | |
| SCHEMBL131029 | 0.86 | LMNA (0.61) | LMNACA1TSHRMAPTALDH1A1 | |
| SCHEMBL15315589 | 0.84 | LMNA (0.64) | LMNACA1TSHRMAPTALDH1A1 | |
| SCHEMBL72471 | 0.84 | LMNA (0.62) | LMNATSHRMAPTHTTCYP2D6 | |
| SCHEMBL28541740 | 0.83 | LMNA (0.52) | LMNATSHRMAPTHTTCYP2D6 | |
| SCHEMBL23628387 | 0.82 | LMNA (0.68) | LMNACA1MAPTALDH1A1 | |
| SCHEMBL8088310 | 0.82 | LMNA (0.68) | LMNACA1MAPTALDH1A1 | |
| SCHEMBL28495155 | 0.82 | LMNA (0.62) | LMNACA1TSHRMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110981873-B | Preparation method for synthesizing pyrroloquinoline quinone by five-step method | 江西农业大学 | 2025-01-24 | — | — | CN | claimed |
| EP-0188805-B1 | 1,3-DITHIOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-09-06 | — | — | EP | claimed |
| EP-4583177-A1 | METHOD OF MANUFACTURING ELECTRODE, COMPOSITE ELECTRODE, ELECTROCHEMICAL ELEMENT, AND APPARATUS FOR MANUFACTURING ELECTRODE | Ricoh Company, Ltd. (JP) | 2025-07-09 | — | — | EP | disclosed |
| CN-110981873-B | Preparation method for synthesizing pyrroloquinoline quinone by five-step method | 江西农业大学 | 2025-01-24 | — | — | CN | disclosed |
| CN-118401537-A | Pyridoxal-5-phosphate (P5P) analogues | 加美生物研究公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240218023-A1 | CYCLIC PEPTIDE-N-ACETYLGALACTOSAMINE (GALNAC) CONJUGATES FOR DRUG DELIVERY TO LIVER CELLS | MICROBIO (SHANGHAI) CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| EP-4362128-A1 | LIQUID COMPOSITION, METHOD FOR PRODUCING LIQUID COMPOSITION, ELECTRODE, ELECTRODE PRODUCTION APPARATUS, AND METHOD FOR PRODUCING ELECTRODE | Ricoh Company, Ltd. (JP) | 2024-05-01 | — | — | EP | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20230399356-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-14 | — | — | US | disclosed |
| CN-111801100-B | 7-substituted sulfoimidoyl purinone compounds and derivatives for the treatment and prevention of liver cancer | 豪夫迈·罗氏有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20110009615-A1 | METHOD FOR PRODUCING A STEROID COMPOUND | MITSUBISHI CHEMICAL GROUP SCIENCE AND TECHNOLOGY RESEARCH CENTER, INC. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20100063272-A1 | METHOD FOR PRODUCING STEROID COMPOUND | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-03-11 | — | — | US | disclosed |
| US-7662977-B2 | PI-3 kinase inhibitor prodrugs | SEMAFORE PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| US-20080188423-A1 | PI-3 KINASE INHIBITOR PRODRUGS | SIGNALRX PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-7396828-B2 | PI-3 kinase inhibitor prodrugs | SEMAFORE PHARMACEUTICALS, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080107747-A1 | Capsaicin, an inflammation control component , a mixture of menthyl lactate, ethyl menthane carboxamide, and methyl diisopropyl propionamide, and menthone glycerin acetal, a heat absorbing component, circulation increasing component, anti-inflammatory complex; extended and time controlled release | UNION BANK OF CALIFORNIA, N.A., AS ADMINISTRATIVE AGENT | 2008-05-08 | — | — | US | disclosed |
| US-7282224-B1 | Pain relief composition | GUTHY-RENKER CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | LMNA 3423/4885CA1 4577/4885TSHR 2611/4885 |
| US-20110009615-A1 | METHOD FOR PRODUCING A STEROID COMPOUND | CYP46A1, DHCR7, CYP17A1 | LMNA 1858/4885CA1 1032/4885TSHR 3395/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | LMNA 4639/4885CA1 4523/4885TSHR 179/4885 |
| US-20240218023-A1 | CYCLIC PEPTIDE-N-ACETYLGALACTOSAMINE (GALNAC) CONJUGATES FOR DRUG DELIVERY TO LIVER CELLS | GALNT1, CSGALNACT1, GALNT2 | LMNA 1541/4885CA1 762/4885TSHR 1210/4885 |
| US-20230399356-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | LMNA 4539/4885CA1 4828/4885TSHR 3003/4885 |
| US-20080188423-A1 | PI-3 KINASE INHIBITOR PRODRUGS | PI4KA, PI4KB, PI4K2B | LMNA 3669/4885CA1 3274/4885TSHR 3974/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | LMNA 1679/4885CA1 2208/4885TSHR 1420/4885 |
| US-20100063272-A1 | METHOD FOR PRODUCING STEROID COMPOUND | CYP46A1, DHCR7, HSD17B7 | LMNA 1608/4885CA1 1800/4885TSHR 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.